Compare Ascendis Pharma A/S (ASND) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Hormel Foods Corp — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while Hormel Foods Corp trades at $24.59 (market cap $13.61B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Hormel Foods Corp pays a 4.73% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HRL | |
|---|---|---|
Market Cap | $17.74B | $13.61B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $30.51 |
52-Week Low | $163.32 | $19.74 |
Enterprise Value | $18.11B | $15.61B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Hormel Foods (HRL) trades at $24.735, up 1.66% today, with a bearish technical signal but consistent earnings beats in recent quarters. The company maintains a 60-year dividend growth streak, paying $0.29 quarterly, while navigating margin pressures with a 3.82% net income margin. Recent news highlights strategic moves like the Ceratti Brazil sale to sharpen growth focus, though revenue trends remain flat near $12.1B.
Outlook is mixed: valuation appears reasonable (P/E 29.09, P/S 1.11) with analyst consensus at $26.00, but risks include volatile cash flows and competitive pressures. The stock offers income stability via dividends, yet investors face headwinds from inflation and sluggish profit growth, requiring patience for a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
